IDYA supply chain intelligence for IDEAYA Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
IDEAYA Biosciences, Inc. (IDYA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 92% | AstraZeneca will supply Imfinzi ® . |
| AZN | AstraZeneca PLC | 92% | Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN grap… |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross proceeds of … |
| BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with Biocytogen Pharmaceut… |
| GSK | GSK plc | 90% | Reciprocal relationship from GSK graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from GSK graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from GSK grap… |
| JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Jiangsu Hengrui Pharmaceuticals … |
| NVS | Novartis AG | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Novartis |
| NVS | Novartis AG | 90% | Reciprocal relationship from NVS graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from IDYA graph: timing and amount of any milestone, r… |
| UNIVERSITY-OF-MANCHESTER | UNIVERSITY-OF-MANCHESTER | 90% | timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Option and License Agreement with CRT and University of… |
| HENGRUI-PHARMA | HENGRUI-PHARMA | 85% | IDE849/SHR-4849 (licensed from Hengrui Pharma) |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IDYA graph: sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical tria… |
| GILD | Gilead Sciences, Inc. | 72% | sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical trial, IDE161 (PARG) Phase 1/2 clinical trial, IDE275 (Werner Helicase) Phase 1 clinic… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit… |
| MANU | Manchester | 72% | mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SERVIER | SERVIER | 90% | The Company has financed its operations primarily through the sale and issuance of common stock, the upfront payment and certain milestone payments received from GSK (as defined below) and the upfron… |
| AZN | AstraZeneca PLC | 72% | to each performance obligation by the amount that the entity expects to receive for transferring the goods or services. Since evidence based on observable prices is not available for the performance … |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IDYA graph: Reciprocal relationship from AZN grap… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from IDYA graph: mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit… |
| MANU | Manchester | 72% | mbined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctuate significantly, which wil… |
| BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | BIOCYTOGEN-PHARMACEUTICALS-CO-LTD | 62% | eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu… |
| FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC | FOR-IDE397-SERVIER-PHARMACEUTICALS-LLC | 62% | uthority disagreeing as to the design or implementation of our clinical trials; • delays in obtaining regulatory authorization to commence a clinical trial; • reaching agreement on acceptable terms w… |
| JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | 62% | eriods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. Our operating results may fluctu… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IDYA-DEBT-10192 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| IDYA-DEBT | Debt stack $28.6M | 90% | Market cache reports total debt of $28.6M. |
| IDYA-DEBT-10191 | Warrants outstanding: 285715 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IDYA-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 260 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| AAUAF | Almaden Minerals Ltd. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CBAN | Colony Bankcorp, Inc. | 100.00 | 2 | |
| ALCY | Alchemy Investments Acquisition Corp 1 | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| RYAOF | Ryanair Holdings plc | 100.00 | 2 | |
| AUGO | Aura Minerals Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| BANL | CBL International Limited | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| ALGM | Allegro MicroSystems, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DGNX | Diginex Limited | 100.00 | 2 |